Related Experiment Video
Updated: Feb 10, 2026

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
The Synergy between a Silver-Ruthenium Antimicrobial and aminoglycosides is based on severe macromolecular damage
Emmanuel P Oladokun1, Gracious Y Donkor1, Julius K Narh1
1School of Biological Sciences, Illinois State University, Normal, IL.
Abstract:
The rise of multidrug-resistant (MDR) bacterial pathogens, including uropathogenic Escherichia coli (UPEC), highlights the urgent need for alternative treatment strategies to restore antibiotic efficacy. The silver-ruthenium antimicrobial AGXX® exerts potent bactericidal effects through the production of reactive oxygen species (ROS); however, its potential synergy with antibiotics has not been thoroughly investigated. Here, we show that sublethal concentrations of AGXX® strongly enhance aminoglycoside-mediated killing across a diverse panel of Gram-negative and Gram-positive MDR clinical isolates, including highly aminoglycoside-resistant strains. Combinational treatments significantly reduced the effective concentrations of gentamicin, tobramycin, kanamycin, and amikacin required for bacterial killing. Mechanistic analyses revealed that AGXX®/aminoglycoside co-treatment induces pronounced intracellular ROS accumulation, resulting in severe proteotoxic stress, extensive protein aggregation, and DNA damage. Scavenging ROS abolished synergistic killing, establishing oxidative imbalance as the primary driver of the synergy between both antimicrobials. We further identify polyphosphate as a key bacterial defense mechanism that mitigates ROS accumulation, proteotoxicity, and genotoxic stress during combinational treatment. Moreover, AGXX®-aminoglycoside synergy was preserved in an artificial urine medium and across clinical UPEC isolates, underscoring its relevance to urinary tract infections. Together, these findings position AGXX® as a potent aminoglycoside adjuvant that restores antibiotic efficacy through ROS-driven macromolecular damage, supporting its development for combination therapies against MDR bacterial infections.
Insights
The silver-ruthenium antimicrobial AGXX enhances aminoglycoside antibiotics, restoring their efficacy against multidrug-resistant bacteria. This combination therapy combats infections by increasing reactive oxygen species (ROS) and damaging bacterial cells.
Area of Science:
- Antimicrobial resistance
- Nanotechnology in medicine
- Bacterial pathogenesis
Background:
- Multidrug-resistant (MDR) bacterial infections pose a significant global health threat.
- Uropathogenic Escherichia coli (UPEC) is a common cause of urinary tract infections (UTIs).
- Novel strategies are needed to restore the efficacy of existing antibiotics.
Purpose of the Study:
- To investigate the synergistic potential of the silver-ruthenium antimicrobial AGXX® with aminoglycoside antibiotics.
- To explore the mechanisms underlying any observed synergy.
- To assess the efficacy of AGXX®-aminoglycoside combinations against MDR clinical isolates, including UPEC.
Main Methods:
- Testing AGXX® in combination with gentamicin, tobramycin, kanamycin, and amikacin against MDR Gram-negative and Gram-positive bacteria.
- Measuring intracellular reactive oxygen species (ROS) levels, proteotoxic stress, protein aggregation, and DNA damage.
- Evaluating the role of ROS in synergistic killing by using ROS scavengers.
- Investigating bacterial defense mechanisms, including polyphosphate.
- Assessing efficacy in an artificial urine medium and against clinical UPEC isolates.
Main Results:
- Sublethal AGXX® concentrations significantly potentiated aminoglycoside-mediated bacterial killing.
- Combinations reduced the effective concentrations of multiple aminoglycosides against resistant strains.
- AGXX®/aminoglycoside co-treatment induced substantial intracellular ROS accumulation, proteotoxic stress, and DNA damage.
- ROS scavenging abolished the synergistic killing effect.
- Polyphosphate was identified as a bacterial defense mechanism against ROS-induced damage.
- Synergy was maintained in artificial urine and against clinical UPEC isolates.
Conclusions:
- AGXX® acts as a potent adjuvant, restoring aminoglycoside efficacy against MDR bacteria.
- The synergy is driven by ROS-induced macromolecular damage.
- AGXX®-aminoglycoside combination therapy shows promise for treating MDR bacterial infections, particularly UTIs.
- Further development of AGXX® for combination therapies is warranted.
Related Concept Videos
Estimation of k and VD of Aminoglycosides
Antimicrobial Effectiveness
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

